Consistent with this notion, AMG 330 was broadly active in our set of AML specimens across the entire cytogenetic/molecular disease spectrum not only in specimens from previously untreated AML patients but also in those from patients who failed conventional chemotherapeutic treatments and regardless of Pgp activity. This evidence concerns the gene PGP and acute myeloid leukemia.